SUCCESSFUL TREATMENT OF RECALCITRANT CANDIDAL INTERTRIGO WITH DR MICHAELS® (FUNGATINEX®) PRODUCT FAMILY


12nd Medical Faculty, Charles University, Bulovka Hospital, 2Institute of Clinical and Experimental Medicine, Prague, Czech Republic; 3Psoriasis & Skin Clinic, Melbourne, Australia; 4Department of Nuclear Physics, Sub-nuclear and Radiatiion, Guglielmo Marconi University, Rome, Italy; 5Dermatological Department University of Pisa, Pisa, Italy; 6"Onkoderma"-Policlinic for dermatology and dermatologic surgery, Sofia, Bulgaria; 7Department of Dermatology and Venereology, Medical University of Plovdiv, Medical faculty, Plovdiv, Bulgaria; 8Medical Institute of Ministry of Interior (MVR), Department of Dermatology, Venereology and Dermatologic Surgery, Sofia, Bulgaria; 9Department of Dermatology and Allergology, Academic Teaching Hospital Dresden-Friedrichstadt, Dresden, Germany; 10PRO SANUM Ltd, Sanatorium of Prof. Novotny, Štěpánská Prague 1 Czech Republic; 11University B.I.S. Group of Institutions, Punjab Technical University, Punjab, India; 12Department "Medicinal Information and Non-interventional studies", Bulgarian Drug Agency, Sofia, Bulgaria; 13Department of Dermatology & Cutaneous Surgery, Department of Psychiatry & Behavioral Sciences, Institute for Bioethics & Health Policy, University of Miami, Miller School of Medicine, Miami, FL, USA; 14Centro Studi per la Ricerca Multidisciplinare e Rigenerativa, Università Degli Studi "G. Marconi", Rome, Italy; 15Chair of Dermatology, University of Rome "G. Marconi" Rome, Italy

Candidal intertrigo is an infection of the skin caused by Candida albicans that typically occurs in opposing cutaneous or muco-cutaneous surfaces. Because Candidiasis requires a damaged and moist environment for infection, it typically occurs in areas of friction such as the skin folds of the body. Candidal intertrigo is often difficult to treat and results are often unsatisfactory. In addition, there is a lack of evidence-based literature supporting prevention and treatments for candidal intertrigo. The aim of the study was to evaluate the efficacy of Dr Michaels® (also branded as Fungatine X®) products in the treatment of fungal intertrigo, in 20 women and 2 men with a mean age of 72. Five patients (3 female and 2 male) had type 2 diabetes and 16 (14 female and 2 male) were obese. The patients were treated with Dr Michaels® (Fungatine X®) moisturising bar, topical ointment (twice daily application) and oral herbal formulation, PSC 200 two tablets twice daily with food. After 2 weeks of treatment, the lesions had mostly resolved in all patients with only slight erythema evident. After six weeks of treatment using the moisturising bar, topical ointment and oral herbal formulations from the Dr Michaels® (Fungatine X®) product family, the lesions had totally resolved in 18 patients, while 4 patients had to continue the therapeutic protocol for another 2 weeks. Our results demonstrate that the Dr Michaels® (Fungatine X®) complementary product family is efficacious in the treatment of recalcitrant candidal intertrigo. Furthermore, this study highlights that the Dr Michaels® (Fungatine X®) product family is fast-acting and well tolerated with no serious adverse events reported. These data have important implications for resistant cases of candidal intertrigo where traditional therapies have failed.